SELECTED LECTURES AND PRESENTATIONS

1. "Steroid hormones: Interactions with plasma membranes of target cells." Presented at Department of Nutrition and Food Science, Massachusetts Institute of Technology, Cambridge (1980).
   
   
2. "Membrane actions of steroid hormones." Presented at Department of Urology Seminar Series, Johns Hopkins University School of Medicine, Baltimore (1980).
   
   
3. "Molecular properties of estrogen receptors from target cell membrane." Presented at Heritage Medical Foundation Lecture Series in Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Calgary, Canada (1982).
   
   
4. "Cathepsins and Cancer." Presented at Hematology-Oncology Lecture Series, Department of Medicine, University of California, Los Angeles (1990).
   
   
5. "Strategies for treatment of HER-2/neu-expressing cancer cells." Presented at Cancer Center, University of California, San Diego (1991).
   
   
6. "Variant estrogen receptors in breast cancer." Presented at Oncology Lecture Series, Jonsson Comprehensive Cancer Center, University of California, Los Angeles (1992).
   
   
7. "Potentiation of platinum cytotoxicity by anti-HER-2/neu monoclonal antibodies". Presented at USC / Norris Comprehensive Cancer Center Consortium - New Directions with Platinum Compounds, Los Angeles (1994).
   
   
8. "HER-2 tyrosine kinase targets estrogen receptor in human breast cancer". Presented at Genentech, Division of Protein Chemistry Seminar, South San Francisco (1994).
   
   
9. "Reversal of human breast cancer cell growth and angiogenesis on combined therapy with antibodies to HER-2/neu receptor and to vascular endothelial cell growth factor". NCI SPORE Investigators Meeting, Rockville, MD (1994) .
   
   
10. "Angiogenesis in human cancer". Molecular and Cellular Foundations of Disease Seminar, University of California, Los Angeles (1995).
    
    
11. "Cross-talk between estrogen receptor and HER-2 growth factor signaling pathways". Jonsson Comprehensive Cancer Center Research Conference, UCLA (1996).
    
    
12. "New endocrine strategies to prevent breast cancer progression". BCRP California Breast Cancer Research Symposium, Sacramento Convention Center, CA (1997).
    
    
13. "Alteration of the HER-2/neu gene in human breast cancer: diagnostic and therapeutic implications- Parts I and II". Breast Cancer Symposium (sponsored by Continuing Medical Education Committee), Sierra Medical Center, El Paso, Texas (1997).
    
    
14. "HER-2 tyrosine kinase pathway regulates estrogen receptor and growth in human breast cancer cells" (Invited Platform Presentation). Department of Defense Breast Cancer Research Program Meeting : Era of Hope, Washington, DC (1997).
    
    
15. "New antiestrogens for treatment of human breast cancer". Signal Transduction & Cancer Mini-Symposium, UCLA (1998).
    
    
16. "Herceptin: Evolution of a new breast cancer treatment from the bench to the bedside". Breast Cancer Awareness Seminar, Los Robles Comprehensive Cancer Center (1998).
    
    
17. "New treatment approaches for metastatic breast cancer". Los Angeles County Oncology Nurses Association, Annual Meeting (1998).
    
    
18. "Estrogen receptor in breast cancer". M294 - Molecular Basis of Cancer Lectures, UCLA School of Medicine (1999).
    
    
19. "Introduction to the Cellular and Molecular Biology of Cancer". M298C Seminar, UCLA School of Medicine (1999).
    
    
20. "Estrogen receptor and HER-2 tyrosine kinase interactions in human breast cancer". Invited platform speaker for FASEB Summer Research Conferences, Copper Mountain, Colorado (1999).
    
    
21. "HER-2 Receptor-Directed Therapy for Breast Cancer". Invited platform speaker for Plenary Session on Emerging Breast Cancer Treatments, California Breast Cancer Research Symposium (1999).
    
    
22. "Small Molecule Inhibitors of Estrogen Receptor Function". Presented at Molecular Oncology Seminar, Genentech, South San Francisco (1999).
    
    
23. "Membrane estrogen receptors in human breast cancer". Presented at Department of Biochemistry and Molecular Biology Seminar Series, University of Texas Medical Branch, Galveston, Texas (2000).
    
    
24. "Interactions between Type I receptor tyrosine kinases and steroid hormone receptors". Presented at First International Congress on Translational Research in Oncology, Dublin, Ireland (2001).
    
    
25. "Integrative approaches to cancer therapy". Presented at Sixth Annual Conference of UCLA Center for East-West Medicine, Los Angeles (2001).
    
    
26. "Monoclonal antibodies for antitumor therapy". Presented at Immunobiology of Cancer Seminar (MI 262A), UCLA (4/2002).
    
    
27. "Steroid and growth factor receptors in breast cancer : cross-talk and clinical implications". Presented at Second International Congress on Translational Research in Oncology, Anaheim, CA (2002).
    
    
28. "Clinical exploitation of interactions between estrogen and HER-2 receptors in human breast cancer". Presented at 8th Annual Multidisciplinary Symposium on Breast Disease, A Program of the University of Florida Health Science Center and the Susan G. Komen Breast Cancer Foundation, Amelia Island, Florida (2003).
    
    
29. "Estrogen and HER-2 receptor interactions in human breast cancer". Presented at Symposium on Steroid Hormone Action at American Society for Cell Biology Annual Meeting, San Francisco, CA (2003).
    
    
30. "Interactions of estrogen and HER-2 receptors in human breast cancer". To be presented at FASEB Summer Research Conference on Steroid Hormone Receptors, Omni Resort, Tucson, Arizona (2004).
    
    
31. "Mechanisms of endocrine resistance in human breast cancer therapy". To be presented at Meet the Professor session at the 2004 American Society for Clinical Oncology (ASCO) Annual Meeting, New Orleans (2004).
    
    
32. "Dual therapy with Faslodex and Herceptin in human breast cancer". To be presented at Breast Cancer Summit, Montreaux, Switzerland (2004).
    
    
33. "Membrane-associated estrogen receptor signaling and implications for breast cancer therapy". To be presented at International Symposium on Steroid Hormone Receptors, Gandi Center, Kerala, India (2004).
    
    

BIBLIOGRAPHY

I. PEER-REVIEWED JOURNALS

A. RESEARCH PAPERS

1. Pietras, R.J. and E.M. Wright (1974). Nonelectrolyte probes of membrane structure in ADH-treated toad urinary bladder. Nature 247: 222-224.
   
   
2. Wright, E.M. and R.J. Pietras (1974). Routes of nonelectrolyte permeation across epithelial membranes. J. Membrane Biol. 17: 293-312.
   
   
3. Bindslev, N., J. McD.Tormey, R.Pietras and E.Wright (1974). Electrically and osmotically induced changes in permeability and structure of toad urinary bladder. Biochem. Biophys. Acta 332: 286-294.
   
   
4. Pietras, R.J. and D.G. Moulton (1974). Hormonal influences on odor detection in rats: changes associated with the estrous cycle, estrogens and testosterone. Physiol. Behav. 12: 475-491.
   
   
5. Pietras, R.J. and B.M. Wenzel (1974). Effects of gonadal steroids on body weight, feeding and courtship behavior in the pigeon. Hormomes and Behavior 5: 289-302.
   
   
6. Pietras, R.J. and D.G. Moulton (1975). Effects of gonadal steroids on odor detection performance in the rat. Olfaction and Taste 5: 403-409.
   
   
7. Pietras, R.J. and E.M. Wright (1975). The membrane action of antidiuretic hormone (ADH) on toad urinary bladder. J. Membrane Biol. 22: 107-123.
   
   
8. Pietras, R.J. and C.M. Szego (1975). Steroid hormone-responsive isolated endometrial cells. Endocrinology 96: 946-954.
   
   
9. Pietras, R.and C.Szego (1975). Endometrial cell calcium and oestrogen action. Nature 253: 357-359.
   
   
10. Pietras, R.J., B.J. Seeler and C.M. Szego (1975). Influence of antidiuretic hormone on release of lysosomal hydrolase at mucosal surface of epithelial cells from urinary bladder. Nature 257: 493-495.
    
    
11. Pietras, R.J., P.J. Naujokaitis and C.M. Szego (1975). Surface modifications evoked by antidiuretic hormone in isolated epithelial cells. J. Supramolecular Structure 3: 391-400.
    
    
12. Pietras, R.J. and C.M. Szego (1975). Surface modifications evoked by estradiol and diethylstilbestrol in isolated endometrial cells: Evidence from lectin probes and extracellular release of lysosomal protease. Endocrinology 97: 1445-1454.
    
    
13. Pietras, R.J., P.J. Naujokaitis and C.M. Szego (1976). Differential effects of vasopressin on the water, calcium and lysosomal enzyme contents of mitochondria rich and lysosome-rich (granular) epithelial cells from isloated bullfrog urinary bladder. Mol. Cell. Endocrinology 4: 89-106.
    
    
14. Pietras, R.J. (1976). Vasopressin-induced redistribution of binding-sites for concanavalin A at the surfaces of epithelial cells from urinary bladder. Nature 264: 774-776.
    
    
15. Pietras, R.J. and C.M. Szego (1976). Early membrane alterations in isolated cells treated in vitro with chemical carcinogens. Cancer Letters 1: 237-242.
    
    
16. Pietras, R.J. and C.M. Szego (1977). Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 265: 69-72.
    
    
17. Pietras, R.J. (1978). Heritable membrane alterations and growth associated with enhanced leupeptin-sensitive proteinase activity in epithelial cells exposed to dibutylnitrosamine in vitro. Cancer Res. 38: 1019-1030.
    
    
18. Pietras, R.J., C.M. Szego, C.E. Mangan, B.J. Seeler, M.M. Burtnett and M. Orevi (1978). Elevated serum cathepsin B and vaginal pathology after prenatal DES exposure. Obstet. Gynecol. 52: 321-327.
    
    
19. Pietras, R.J. and C.M. Szego (1979). Metabolic and proliferative responses to estrogen by hepatocytes selected for plasma membrane binding-sites specific for estradiol-17B. J. Cellular Physiol. 98: 145-159.
    
    
20. Pietras, R.J., C.M. Szego, C.E. Mangan, B.J. Seeler and M.M. Burtnett (1979). Elevated serum cathepsin B-like activity in women with neoplastic disease. Gynecol. Oncol. 7: 1-17.
    
    
21. Pietras, R.J. and C.M. Szego (1979). Estrogen-induced membrane alterations and growth associated with proteinase activity in endometrial cells. J. Cell Biol. 81: 649-663.
    
    
22. Pietras, R.J. and C.M. Szego (1979). Estrogen receptors in uterine plasma membrane. J. Steroid Biochem. 11: 1471-1483.
    
    
23. Pietras, R.J. and C.M. Szego (1980). Partial purification and characterization of oestrogen receptors in subfractions of hepatocyte plasma membrane. Biochem. J. 191: 743-760.
    
    
24. Pietras, R.J., C.M. Szego, J.A. Roberts and B. Seeler (1981). Lysosomal cathepsin B-like activity: Mobilization in prereplicative and neoplastic epithelial cells. J. Histochem. Cytochem. 29: 440-450.
    
    
25. Pietras, R.J., C. Szego and B. Seeler (1981). Immunologic inhibition of estrogen binding and action in preputial-gland cells and their subcellular fractions. J. Steroid Biochem. Mol. Biol. 14: 679-691.
    
    
26. Pietras, R.J. and J.A. Roberts (1981). Cathepsin B-like enzymes: Subcellular distribution and properties in neoplastic and control cells from human ectocervix. J. Biol. Chem. 256: 8536-8544.
    
    
27. Pietras, R.J. (1982). Sex pheromone production by preputial gland : The regulatory role of estrogen. Chemical Senses 6: 391-408.
    
    
28. Pietras, R.J. and C.M. Szego (1984). Specific internalization of estrogen and binding to nuclear matrix in isolated uterine cells. Biochem. Biophys. Res. Comun. 123: 84-91.
    
    
29. Szego,C.M. and R.J. Pietras (1985). Subcellular distribution of oestrogen receptors. Nature 317: 88-90.
    
    
30. Pietras, R.J., B.M. Fendly, V. Chazin, M.D. Pegram, S.B. Howell and D.J. Slamon (1994). Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9 : 1829-1838.
    
    
31. Pietras, R. J., J. Arboleda, D. Reese, N. Wongvipat, M. Pegram, L. Ramos, C. M. Gorman, M.G. Parker, M. X. Sliwkowski, and D. J. Slamon (1995). HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10 : 2435-2446.
    
    
32. Nguyen M., C. Tran, S. Barsky, J.-R. Sun, W. McBride, M. Pegram, R. Pietras, S. Love and J. Glaspy (1997). Thalidomide and chemotherapy combination: preliminary results of preclinical and clinical studies. Int. J. Oncology 10: 965-969.
    
    
33. Pegram, M.D., R.S. Finn, K. Arzoo, M. Beryt, R.J. Pietras and D.J. Slamon (1997). The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15: 537-547.
    
    
34. Pietras, R.J., M.D. Pegram, R.S. Finn, D.A. Maneval and D.J. Slamon (1998). Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17: 2235-2249.
    
    
35. Pietras, R.J. and M.D. Pegram (1999). Oncogene activation and breast cancer progression. Contemporary Endocrinology, 11 : 133-153.
    
    
36. Pietras, R.J. (1999). Peptide antiestrogen compositions and methods for treating breast cancer. PCT Gazette : 2222-2232.
    
    
37. Pietras, R.J., J. Poen, D. Gallardo, P.N. Wongvipat, H.J. Lee and D.J. Slamon (1999). Monoclonal antibody to HER-2 receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells. Cancer Research, 59 : 1347-1355.
    
    
38. Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar F., and Slamon, D. (1999). Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene, 18 : 2241-2251.
    
    
39. Aguilar Z., R.W. Akita, R.S. Finn, B. L. Ramos, M.D. Pegram, F. F. Kabbinavar, R.J. Pietras, P. Pisacane, M. X. Sliwkowski and D.J. Slamon (1999). Biologic effects of heregulin / neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene, 18: 6050-6062.
    
    
40. Pietras, R.J., I. Nemere and C.M. Szego (2001). Steroid hormone receptors in target cell membranes. Endocrine, 14 : 417-427.
    
    
41. Marquez, D. and R.J. Pietras (2001). Membrane-associated binding sites for estrogen contribute to growth regulation in human breast cancer cells. Oncogene, 20 : 5420-5430.
    
    
42. Marquez, D., J. Lee, T. Lin and R.J. Pietras (2001). Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor. Endocrine (in press).
    
    
43. Pietras, R.J., I. Nemere and C.M. Szego (2001). Steroid hormone receptors in target cell membranes. Endocrine, 14 : 417-427.
    
    
44. Marquez, D. and R.J. Pietras (2001). Membrane-associated binding sites for estrogen contribute to growth regulation in human breast cancer cells. Oncogene, 20 : 5420-5430.
    
    
45. Marquez, D., J. Lee, T. Lin and R.J. Pietras (2001). Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor. Endocrine, 16 : 73-81.
    
    
46. Li, D., J. I. Williams and R.J. Pietras (2002). Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with and without HER-2 gene overexpression. Oncogene 21 : 2805-2814.
    
    
47. Nemere, I, RJ Pietras and PF Blakemore (2003). Membrane receptors for steroid hormones: Signal transduction and physiological significance. J. Cell. Biochem. 88: 438-445.
    
    
48. Pietras, RJ, M Gorrin-Rivas and H-W Chen (2003). Squalamine blocks tumor-associated angiogenesis and growth of ovarian cancer. Int. J. Gynecol. Obstet. 83, Suppl 3 : 59-61.
    
    
49. Pietras, R.J. (2003). Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. The Breast Journal 9: 361-373.
    
    
50. Pegram MD, Konecny GE, O’Callaghan CO, Beryt M, Pietras RJ and Slamon DJ (2004). Rational combinations of Trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl. Cancer Inst. 96(10):739-49.
    
    
51. Garban, HJ, DC Marquez, RJ Pietras and LJ Ignarro (2005). Rapid nitric oxide-mediated S- nitrosylation of estrogen receptors and regulation of specific estrogen-dependent gene transcription. Proc. Natl. Acad. Sci. USA 102 : 2632-2636.
    
    
52. Pietras RJ, Marquez DC, Chen H-W, Tsai E, Weinberg O and Fishbein M (2005). Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 70: 372-381.
    
    
53. Dowsett M, Nicholson RI and Pietras RJ (2005). Fulvestrant- a unique endocrine agent. Breast Cancer Res Treatment 93, Suppl 1: 11-18.
    
    
54. Weinberg OK, Marquez-Garban DC, Fishbein MC, Goodglick L, Garban HJ, Dubinett S and Pietras RJ (2005). Aromatase inhibitors in human lung cancer therapy. Cancer Research 65 : 11287-11293.
    
    
55. Pio BS, Park CK, Pietras R, Hsueh W-A, Satyamurthy N, Pegram M, Czernin J, Phelps ME, Silverman DH (2006). Usefulness of 3-deoxy-3-[18F]fluorothymidine with positron emission tomography in predicting breast cancer response to therapy. Molecular Imaging and Biology 8: 36-42.
    
    
56. Marquez DC, Chen HW, Welshons WV and Pietras RJ (2006). Estrogen receptor in membrane lipid rafts and signal transduction in breast cancer. Molecular Cellular Endocrinol 246: 91-100.
    
    
57. Pietras, RJ (2006). Biologic Basis of Sequential and Combination Therapies for Hormone-Responsive Breast Cancer. The Oncologist 11(7); 704-17.
    
    
58. Sartippour MR, Pietras R, Marquez-Garban DC, Chen H-W, Heber D, Henning SM, Sartippour G, Zhang L, Lu M, Weinberg O, Rao JY and Brooks MN (2006). The combination of green tea and tamoxifen is effective against breast cancer. Carcinogenesis 27(12); 2424-33.
    
    
59. Marquez DC, Chen HW, Curran EM, Welshons WV, Pietras RJ. (2006). Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer . Mol Cell Endocrinol 246(1-2); 91-100.
    
    
60. Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, Czernin J, Phelps ME, Silverman DH (2006). Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 8(1); 36-42.
    
    
61. Marquez-Garban DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ. (2007). Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 72(2):135-43. Epub 2007 Feb 5.
    
    

II. INVITED REVIEWS

1. Szego, C.M. and R.J. Pietras (1981). Membrane recognition and effector sites in steriod hormone action. In: Biochemical Actions of Hormones, Vol. VIII (G. Litwack, editor), Academic Press, New York, pp. 307-464.
   
   
2. Pietras, R.J. and C.M. Szego (1982). Estrogen-induced growth of uterine cells: Evidence for involvement of surface membranes, calcium and proteinase activity. In: Reproductive Processes and Contraception (K.W. McKerns, edtior), Plennum Press, New York, pp. 649-674.
   
   
3. Szego, C.M. and R. J. Pietras (1984). Lysosomal function in cellular activation: Propagation of the actions of hormones and other effectors. International Reviews of Cytology 88 : 1-302.
   
   
4. Szego, C.M., R.J. Pietras and I. Nemere (2002). Membrane steroid receptors. In : Encyclopedia of Hormones and Related Cell Regulators (Henry, H. and Norman, A., editors), Academic Press, New York (in press).
   
   
5. Pietras, R.J. (2002). Steroid and Growth Factor Receptors : Cross-Talk and Clinical Implications. In: Breast Cancer Management , 2nd Edition (J.-M. Nabholtz and D.J. Slamon, editors), Lippincott, Philadelphia (in press).
   
   
6. Marquez, D.C. and R.J. Pietras (2002). Membrane-associated estrogen receptors in human breast cells. In: Identities of Membrane Steroid Receptors (C. Watson, editor), Kluwer Academic Publishers (in press).
   
   
7. Nemere, I., R.J. Pietras and P.F. Blakemore (2002). Membrane receptors for steroid hormones: Signal transduction and physiological significance. J. Cellular Biochem. (in press).
   
   
8. Szego, C.M., R.J. Pietras and I. Nemere (2003). Membrane steroid receptors. In : Encyclopedia of Hormones and Related Cell Regulators (Henry, H. and Norman, A., editors), Academic Press, New York, pp. 657-671.
   
   
9. Pietras, R.J. (2003). Steroid and Growth Factor Receptors : Cross-Talk and Clinical Implications. In: Breast Cancer Management , 2nd Edition (J.-M. Nabholtz and D.J. Slamon, editors), Lippincott, Philadelphia (in press).
   
   
10. Marquez, D.C. and R.J. Pietras (2003). Membrane-associated estrogen receptors in human breast cells. In: Identities of Membrane Steroid Receptors (C. Watson, editor), Kluwer Academic Publishers : pp. 1-11.
    
    
11. Pietras, RJ and Szego, CM (2005). Plasma membrane receptors for steroid hormones and integration with nuclear function. In: Endocrinology : Basic and Clinical Principles (S. Melmed and PM Conn, editors), Humana Press: pp. 67-84.
    
    
12. Pietras RJ and Weinberg O (2005). Antiangiogenic steroids in human cancer therapy. Evidence-Based Complementary and Alternative Medicine 2: 149- 157.
    
    
13. Pegram M, RJ Pietras, A Bajamonde, P Klein and G Fyfe (2005). Targeted therapy: Wave of the future. J. Clin. Oncol. 23: 1776-1781.
    
    
14. Weinberg OK, Marquez-Garban DC, Pietras RJ (2005). New Approaches to Reverse Resistance to Hormonal Therapy in Human Breast Cancer. Drug Resistance Updates 8 : 219-233.
    
    

III. SHORT COMMUNICATIONS

1. Pietras, R.J. and C.M. Szego (1990). Cathepsin D in breast cancer. New Engl. J. Med. 322:1673-1674.
   
   
2. Pietras, R.J. (1997). HER-2 tyrosine kinase pathway regulates estrogen receptor and growth in human breast cancer cells. Proceedings DOD Breast Cancer Research Program, Vol. 3, pp. 987-988.
   
   
3. Pietras, R.J. (1999). Peptide antiestrogen compositions and methods for treating breast cancer. PCT Gazette : 2222.
   
   
4. Pietras, R.J. and C.M. Szego (1999). Cell membrane estrogen receptors resurface. Nature Medicine 5: 1330.
   
   
5. Pietras, R.J., Marquez, D., Chen, X. and Li, D. (2000). Peptide antagonists of the estrogen receptor block growth of human breast cancer cells. Era of Hope DOD Breast Cancer Research Program Proceedings, 2: 535.
   
   
6. Pietras, RJ (2005). Overview of the FASEB 2004 Summer Research Conference on Steroid Hormone Receptors: Integration of Plasma Membrane and Nuclear-Initiated Signaling in Hormone Action. Steroids 70 : 345-346.
   
   
7. Pietras, RJ, Levin, ER, Szego, CM (2005). Estrogen receptors and cell signaling. Science 310: 51-53.
   
   

V. ABSTRACTS

1. Pietras, R. and E.Wright (1974). Effects of mucosal ADH on toad urinary bladder. Fed.Proc.33: 216.
   
   
2. Pietras, R.J. and C.M. Szego (1974). Estrogen-induced alterations in calcium uptake and organic metabolism in isolated endometrial cells. Endocrinology 94: A-100.
   
   
3. Pietras, R.J. (1976). Colchicine inhibition of vasopressin-induced water flow and redistribution of lectin-binding surface proteins in epithelial cells from urinary bladder. Endocrinology 98: 220.
   
   
4. Szego, C., R. Pietras, M.Nazareno and B.Seeler (1977). Inhibition of estrogen binding and mitogenic response to hormone by antiserum to a lysosomal lipoprotein of preputial gland. Endocrinology 100: 81.
   
   
5. Pietras, R.J. and C.M. Szego (1977). Blockade of estrogen uptake and endometrial cell responese to hormone by colchicine and proteinase inhibitiors. Endocrinology 100: 79.
   
   
6. Pietras, R.J., C.M. Szego, C.E. Mangan, B.J. Seeler, M.M. Burtnett and M. Orevi (1977). Elevated serum cathepsin B1 activity with vaginal adenosis and adenocarcinoma in young women exposed in utero to diethylstilbestrol. Fed. Proc. 36: 387.
   
   
7. Pietras, R.J. and C.M. Szego (1977). Growth responses of liver cells with plasma membrane binding-sites for estradiol-17B. J. Cell Biol. 75: 187a.
   
   
8. Pietras, R.J., T. Hutchens and C. Szego (1978). Hepatocyte plasma membrane subfractions enriched in high affinity, low-capacity binding sites specific for estradiol-17B. Endocrinology 102 (Suppl): 76.
   
   
9. Pietras, R.J. and J.A. Roberts (1981). Cathepin B-like enzyme: Concentration in plasma membranes and nuclei of neoplastic cells from human ectocervix. Federation Proceedings 40: 1695.
   
   
10. Pietras, R.J. (1982). Properties of estrogen-binding macromolecules from uterine cell membranes. Endocrinology 108 (Suppl): 295.
    
    
11. Pietras, R., V. Chazin and D. Slamon (1991). Overexpression of human HER-2/neu proto-oncogene promotes neoplastic transformation of human mammary epithelial cells. J. Cell Biol. 115 : 416.
    
    
12. Pegram, M., R.Pietras and D.Slamon (1992). Monoclonal antibody to HER-2 gene product potentiates cytotoxicity of carboplatin and doxorubicin in human breast tumor cells. Proc.AACR 33 : 442.
    
    
13. Pietras, R.J., S. Scates, S.B. Howell and D.J. Slamon (1992). Monoclonal antibody to HER-2/neu receptor modulates DNA repair and platinum sensitivity in human breast and ovarian carcinoma cells. Proc. Am. Assoc. Cancer Res. 33: 547.
    
    
14. Pegram, M.D., Pietras, R.J., V.R. Chazin, L. Ellis and D.J. Slamon (1993). Effect of erbB-2 (HER-2/neu) overexpression on chemotherapeutic drug sensitivity in human ovarian cancer cells. Proc. Am. Assoc. Cancer Res. 34 : 26.
    
    
15. Pietras, R., M.Pegram, N. Abadi, M.Sliwkowski and D.Slamon (1993). Heregulin promotes growth of human breast cancer cells with HER-2 (erb B2) receptors. Proc. Am. Assoc. Cancer Res. 34 : 96.
    
    
16. Aguilar Z., R. Pietras, M.Sliwkowski, and D. Slamon (1993). Biologic effects of HER-2/neu ligand (heregulin) on growth of human breast and ovarian cells. Molecular Biology of Cell, 4 Suppl. : 127a.
    
    
17. Pietras, R.J., M. Pegram, V. Chazin, M. Sliwkowski, N. Ferrara, P. Carter and D.J. Slamon (1994). Novel antitumor and antiangiogenesis therapies for human breast cancer with overexpression of HER-2/neu receptor. SPORE Investigators Meeting 2 : 20.
    
    
18. Pietras, R.J., J. Arboleda, N.Wongvipat, L. Ramos, M.Sliwkowski, and D.J. Slamon (1995). HER-2/neu signaling regulates estrogen receptor in breast cancer. Proc. Am. Assoc. Cancer Res. 36 : 254.
    
    
19. Pegram, M. D., R.J. Pietras, M. Beryt, P. Carter, R. Shalaby and D.J. Slamon (1995). Targeting of HER-2/neu overexpressing breast and ovarian cancers with humanized bispecific F(ab’)2 a p185 HER-2 /a CD3 and human LAK cells in vivo. Proc. Am. Assoc. Cancer Res. 36 : 433.
    
    
20. Pegram, M., A. Lipton, R. Pietras, D. Hayes, B. Weber, J. Baselga, D. Tripathy, T. Twadell, J. Glaspy and D. Slamon (1995). Phase II study of intravenous recombinant humanized anti-p185 HER-2 monoclonal antibody (rhuMAb HER-2) plus cisplatin in patients with HER-2/neu overexpressing metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 14 : 106a.
    
    
21. Pietras, R.J., J.C. Poen, D. Gallardo, P.N.Wongvipat, H.J. Lee, M.X. Sliwkowski and D.J. Slamon (1996). Monoclonal antibody to HER-2 receptor modulates DNA repair and radiation sensitivity in human breast and ovarian cancer cells. Proc. Am. Assoc. Cancer Res. 15: 4166.
    
    
22. Pietras, R.J. and J. Lee (1997). Antitumor effect of phosphotyrosyl-peptides that block binding of estrogen receptor to DNA in human breast cancer cells. Proc. Am. Assoc. Cancer Res. 38 : 174.
    
    
23. Hsu, S., M. Pegram, R. Pietras, M. Beryt and D. Slamon (1997). Therapeutic advantage of chemotherapy drugs in combination with recombinant, humanized anti-HER-2/neu monoclonal antibody (rhuMAb HER-2) against human breast cancer cells and xenografts with HER-2/neu overexpression. Proceedings of AACR Conference on Basic and Clinical Aspects of Breast Cancer 3/12: A39
    
    
24. Pietras, R.J., Marquez, D., Chen, C., Li, D. and Lin, T. (1999). Antitumor effects of peptide antiestrogens that block estrogen receptor binding to steroid receptor coactivator-1 and to DNA in human breast cancer cells. Proc. Am. Assoc. Cancer Res., 40: 637.
    
    
25. Marquez, DC and RJ Pietras (1999). Estrogen receptor in plasma membranes of human breast cancer cells. FASEB Summer Research Conferences.
    
    
26. Pietras, R.J., Li, Diane and Williams, J.I. (2000). Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells. Clin. Cancer Res. (in press).
    
    
27. Marquez, D.C. and R.J. Pietras (2000). Estrogen receptors in plasma membrane regulate growth of human breast cancer cells. Proc.Am.Assoc.Cancer Res., 41: 140.
    
    
28. Pietras, R.J. and H.W. Chen (2001). New radiation therapy for HER-2-overexpressing breast cancer. Proc. California Breast Cancer Research Symposium: 45-46.
    
    
29. Williams, J., Chen, Q., Li., D. and Pietras, R.J. (2001). Squalamine blocks MAP kinase signaling induced by VEGF in human vascular endothelial cells. Proc. Am. Assoc. Cancer Res. 42 : 941.
    
    
30. Pietras, R.J., M.E. Jung, R. Tinder, S. Sugiyama, H.-W. Chen and D.C. Marquez (2002). New antiestrogens for human breast cancer therapy. Proc. Susan G. Komen Breast Cancer Foundation Meeting (in press).
    
    
31. Gorrin-Rivas, M., H.-W. Chen, D. C. Marquez, and R.J. Pietras (2002). Squalamine blocks tumor-associated angiogenesis and promotes antitumor effects of Herceptin in HER-2-overexpressing human breast cancer cells. Proc. Am. Assoc. Cancer Res. 43 : 521-522.
    
    
32. Marquez, DC, H-W Chen, R Tinder, S Sugiyama, M Jung and RJ Pietras (2002). Development of function-specific antiestrogens to block signal transduction by membrane-associated estrogen receptors in human breast cancer cells. Endocrinology (in press).
    
    
33. Garban, HJ, DC Marquez, RJ Pietras and LJ Ignarro (2002). Rapid nitric oxide-mediated S-nitrosylation of estrogen receptors and regulation of specific estrogen-dependent gene transcription. Proc. Internat. Conf. on Biology, Chemistry and Therapeutic Application of Nitric Oxide 2 : (in press).
    
    
34. Davidson, SA, Chap , L, Pietras, RJ, Astrow, A, Gajewski, W, Brader, F, Petrone, M, Desai, A, Solomon, S, Holroyd, K, Major, F, Adler, L and Cohn, A (2002). A Phase IIA trial of continuous 5-day infusions of MSI-1256F (squalamine lactate) plus carboplatin for therapy of persistent or recurrent advanced ovarian cancer. Proc. Am. Soc. Clin. Oncol. : 878.
    
    
35. Marquez DC, Chen, H-W and Pietras RJ (2002). Membrane-associated estrogen receptors localize to caveolae-related domains and contribute to growth regulation of breast cancer cells. Proc. Dept. of Defense Breast Cancer Research Program Meeting 1 : P729.
    
    
36. Marquez DC, Chen, H-W and Pietras RJ (2003). Estrogen receptor forms and HER-2/neu growth factor receptors co-localize in caveolae-related lipid rafts in normal and malignant human breast epithelial cells. Proc. Am. Assoc. Cancer Res. (in press).
    
    
37. Garbán HJ, Marquez DC, Chen H-W, Ignarro LJ and Pietras RJ (2003). Rapid nitric oxide-mediated S-nitrosylation of estrogen receptors: regulation of specific estrogen-dependent gene transcription in the cardioprotective function of estrogen. Proc. Endocrine Soc. 85 (in press).
    
    
38. Pietras RJ, Marquez D, Chen HW, Ayala R, Ramos L and Slamon DJ (2003). Improved antitumor therapy with Herceptin and Faslodex for dual targeting of HER-2 and estrogen receptor signaling pathways in human breast cancers with overexpression of HER-2/neu gene. Breast Cancer Res. Treatment 82, Suppl. 1: 12-13.
    
    
39. Pietras RJ, Chen H-W and Tsai E (2004). Therapeutic targeting of growth factor and estrogen receptor signaling pathways in human non-small cell lung cancer. Proc.Lung Cancer SPORE Meeting, 33-34.
    
    
40. Pietras Pio BS, Park CK, Pietras RJ, Satyamurthy N, Pegram M, Czernin J, Phelps ME and Silverman D (2004). Five minutes of imaging with [F-18]fluoro-L-thymidine (FLT) predicts long-term post-therapy response in breast cancer patients. Proc. Soc. Nucl. Med.: 54-55.
    
    
41. Pietras Rausch R, Chan D, Park C, Pegram M, Northfelt D, Pietras R (2004). A prospective study of memory changes associated with adjuvant chemotherapy in patients with breast cancer. Breast Cancer Research Treatment 88 (Suppl 1): 138.
    
    
42. Pietras Weinberg OK, Marquez DC, Chen H-W, Fishbein M and Pietras RJ (2005). Aromatase inhibitors in human lung cancer therapy. Proc. Am. Assoc. Cancer Res. (in press).
    
    
43. Pietras Pietras RJ, Gorrin-Rivas M, Chen H-W and Marquez DC (2005). Squalamine suppresses tumor-associated angiogenesis and promotes antitumor effects of growth factor receptor inhibitors in breast cancer. Proc. Department of Defense Breast Cancer Research Program Meeting : 126.
    
    
44. Pietras Marquez D, Goodglick L, Mah V, Weinberg O, Garban H, Fishbein M, Chen H-W, Dubinett S, Seligson D and Pietras R (2006). Estrogen Signaling Pathways in Human Lung Cancer: Prognostic and Therapeutic Implications. Proc. Lung Cancer SPORE Meeting :22.
    
    
45. Pietras Sartippour MR, Pietras R, Heber D, Liping Z, Lu M, Brooks M (2006). Green tea effects on estrogen treatment. Proc. Am. Assoc. Cancer Res. 47: 531
    
    
46. Pietras Marquez D, Mah V, Goodglick L, Weinberg O, Garban H, Fishbein M, Chen H-W, Dubinett S, Seligson D and Pietras R (2006). Targeting Estrogen Signaling Pathways for Therapeutic Intervention in Non-Small Cell Lung Cancer. Proc. American Association for Cancer Research (in press).
    
    
47. Pietras Pietras RJ, Marquez DC, Chen HW, Sliwkowski MX, and Slamon DJ (2006). Improved antitumor therapy by dual targeting of estrogen and growth factor receptor signaling in human breast cancer cells. Proc. Am. Soc. Clin. Oncol. (in press).